Chemomab <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Secures FDA Alignment on CMC and Toxicology Milestones, Advancing Phase 3 Development of Nebokitug for PSC
TEL AVIV, Israel, June 11, 2025 -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a clinical stage biotechnology company, announced positive feedback from two recent meetings with the FDA, facilitating the advancement of their drug nebokitug into a Phase 3 clinical trial for Primary Sclerosing Cholangitis $(PSC.AU)$. The FDA has aligned with Chemomab on essential Chemistry, Manufacturing, and Controls $(CMC)$ requirements, ensuring the quality and consistency of the drug supply, and has also agreed to allow non-clinical toxicology studies to proceed concurrently with the Phase 3 clinical trial. This regulatory progress supports the timely advancement of nebokitug's development program as Chemomab continues discussions with potential strategic partners.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Chemomab Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9466553-en) on June 11, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。